Phase I Evaluation of FS222 for Safety and Efficacy in Patients with Advanced Malignancies

The primary objective of this study is to evaluate the **safety** and anti-cancer activity of FS222, an antibody medication, in subjects with **advanced malignancies**. This is a first-in-human study, which is crucial for determining the initial safety profile and potential therapeutic effects of FS222 in a population with limited treatment options. Understanding the safety and efficacy of FS222 could provide valuable insights into its potential as a treatment for advanced cancers.

The clinical trial involves a total of **38 participants** diagnosed with **advanced malignancies**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided information regarding the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed to evaluate the safety and anti-cancer activity of the investigational product FS222, an **antibody** medication, in subjects with **advanced malignancies**. This is a Phase 1 trial, which is typically the first stage of testing in human subjects. The trial follows a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from December 14, 2020, to May 31, 2027, allowing for comprehensive data collection and analysis.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit is crucial for ensuring that only suitable candidates are enrolled in the study. Following enrollment, participants will attend regular follow-up visits, which are scheduled to monitor their health status, assess the safety of the investigational product, and evaluate its efficacy. These visits will include various assessments such as physical examinations, laboratory tests, and imaging studies as required by the protocol. The end-of-study visit marks the conclusion of a participant's involvement, during which final evaluations are conducted to gather comprehensive data on the long-term effects of the treatment.

The expected length of participant involvement in the trial is determined by the study protocol and may vary depending on individual response to the treatment and overall health status. Participants may be subject to early termination from the study if they experience adverse effects that compromise their safety, if they withdraw consent, or if they fail to comply with the study requirements. The trial is conducted in accordance with ethical guidelines and regulatory standards to ensure the safety and well-being of all participants throughout the study duration.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments such as standard-of-care therapy, placebo, or comparator treatment is not available. Additionally, details about drug administration, dosing schedules, and participant compliance monitoring are not included in the source data. Consequently, no further information can be offered regarding the substances used in this study.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating its primary focus on safety and dosage rather than efficacy. However, any preliminary efficacy data collected will be analyzed to inform future studies. The trial is scheduled to run from December 14, 2020, with an estimated end date of May 31, 2027. During this period, data collection will be conducted at predetermined intervals to ensure comprehensive analysis. The specific parameters or endpoints for efficacy assessment are not detailed in the available data. The trial will adhere to standard clinical trial protocols, employing validated methods and instruments for data collection and analysis. The results will contribute to the understanding of the investigational product's potential efficacy, guiding subsequent phases of clinical research.